Research Progress on the Mechanism of TXNIP Protein in Diabetic Complications and Related Markers
DOI:
https://doi.org/10.61173/b052yj86Keywords:
-TXNIP, NLRP3, mechanism, TRX, treat-mentAbstract
TXNIP (Thioredoxin-interacting protein), a key manager of oxidant stress, plays an important role in the pathomechanism of diabetic complications. This review systematically elucidates how TXNIP contributes to diabetic kidney disease (DKD), retinopathy (DR), and peripheral neuropathy through mechanisms involving NLRP3 inflammasome activation and epigenetic modifications. Under high glucose conditions, TXNIP upregulation dissociates from thioredoxin (TRX), binds to NLRP3 via its leucine-rich repeat domain. In DKD, TXNIP overexpression exacerbates renal oxidative stress and mesangial cell apoptosis, while its deficiency preserves β-cell survival and function via AKT/Bcl-xL signaling. In DR, TXNIP inhibition improves angiogenesis and blood-retinal barrier integrity by suppressing NLRP3-mediated inflammation in endothelial cells. Additionally, TXNIP’s role in neurodegenerative diseases are linked to glutamate neurotoxicity and NLRP3 activation. Therapeutic strategies include TIX100, a small-molecule inhibitor targeting TXNIP transcription, which effectively ameliorates diabetes in animal models, and moderate NO levels, which protect retinal cells by directly inhibiting TXNIP/NLRP3 signaling. Future research is needed to optimize TXNIP-based therapies for diabetes and metabolic diseases, highlighting its potential as a diagnostic marker and therapeutic target.
References
[1] K. S. Chen and H. F. Deluca, “Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3,” Biochimica et Biophysica Acta, vol. 1219, no. 1, pp. 26, 1994. J. Zhou, Q. Yu, and W. J. Chng, “TXNIP (VDUP-1, TBP- 2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms,” International Journal of Biochemistry & Cell Biology, vol. 43, no. 12, pp. 1668– 1673, Dec. 2011. H. Tsubaki, I. Tooyama, and D. G. Walker, “Thioredoxin-interacting protein (TXNIP) with focus on brain and neurodegenerative diseases,” International Journal of Molecular Sciences, vol. 21, no. 24, pp. 9357, Dec. 2020. L. Thielen and A. Shalev, “Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 25, pp. 75–80, 2018. G. C. Chau et al., “mTOR controls ChREBP transcriptional activity and pancreatic β cell survival under diabetic stress,” Journal of Cell Biology, vol. 216, no. 7, pp. 2091– 2105, Jul. 2017. J. Chen, G. Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev, “Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis,” Diabetes, vol. 57, no. 4, pp. 938–944, Apr. 2008. S. Y. Park, X. Shi, J. Pang, C. Yan, and B. C. Berk, “Thioredoxin-interacting protein mediates sustained VEGFR2 signaling in endothelial cells required for angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 4, pp. 737–743, Apr. 2013. Y. Sun, Z. Yang, X. Wang, et al., “Thioredoxin-1: A potential target for preventing cardiac reactive oxygen species damage,” Chinese Journal of Thoracic and Cardiovascular Surgery, vol. 30, no. 12, pp. 1779–1783, 2023. Y. Li et al., “Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK,” Toxicology and Applied Pharmacology, vol. 286, no. 1, pp. 53–63, Jul. 2015. S. Jo, G. Jing, J. Chen, G. Xu, and A. Shalev, “Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity,” Diabetes, Obesity and Metabolism, vol. 27, no. 4, pp. 2223–2231, 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
